|
|
Mastering Treatment-Naive nAMD
In this Master Class case, Dr. Priya Vakharia discusses the management of a 72-year-old White man with treatment-naive neovascular age-related macular degeneration. |
|
|
Mastering Suboptimal Treatment Response in nAMD
In this Master Class case, Dr. David Eichenbaum discusses the management of a 69-year-old White man with neovascular age-related macular degeneration who receives a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|